This study evaluated the predictive factors and prognostic value of new-onset persistent left bundle branch block (LBBB) in patients undergoing transcatheter aortic valve implantation (TAVI) with a balloon-expandable valve.
eValve, Medtronic Inc, Minneapolis, Minnesota) (1,2,4 -6,8) . Furthermore, all studies to date have included patients with conduction disturbances prior to TAVI (including patients with prior pacemaker in some), which may indeed lead to a more difficult interpretation of the exact role of TAVI on the development of new conduction disturbances and its predictors.
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Importantly, while it has been shown that the vast majority of conduction disturbances occur during the TAVI procedure, a significant number resolve within the first days following the procedure, especially with the use of a balloon-expandable valve (9, 10) . However, no data exist on the factors associated with persistent (vs. transient) newonset LBBB following TAVI and its clinical consequences. It is therefore unknown whether patients leaving the hospital with a new-onset LBBB following TAVI have a higher risk for clinical events, particularly new-onset complete atrioventricular block (AVB) and/or sudden death. The objectives of this study were therefore to: 1) determine the incidence and predictors of new-onset persistent LBBB in patients without baseline intraventricular conduction abnormalities undergoing TAVI with a balloon-expandable valve; and 2) evaluate the long-term prognostic significance of persistent LBBB in this population.
Methods

Study population.
Of 348 consecutive patients (Quebec Heart & Lung Institute: n ϭ 263; Vall d'Hebron hospital: n ϭ 85), who underwent TAVI with a balloon-expandable valve (Sapien or Sapien XT, Edwards Lifesciences, Irvine LLC, California); 146 patients were excluded because of the following reasons: prior pacemaker (n ϭ 57), prior intraventricular conduction abnormalities (complete or incomplete right or left bundle branch block, n ϭ 83), death, or conversion to open heart surgery before the first ECG (4 and 2 patients, respectively). The final study population consisted of 202 patients. Details about the TAVI procedure have been previously reported (11) . All baseline, procedural, and post-operative data were prospectively recorded. Periprocedural complications were defined according to the Valve Academic Research Consortium criteria (12) . The degree of native aortic valve calcification was measured (in Agatston units) in all patients who had noncontrast ECG-gated computed tomography prior to the procedure (n ϭ 131; 65%). Patients underwent transthoracic echocardiography at baseline, at hospital discharge, and at 6-to 12-month follow-up. The position of the transcatheter valve after implantation was evaluated by transesophageal echocardiography (long-axis view) as previously described (9) . ECG data and criteria for pacemaker implantation. ECG tracings were recorded at baseline (within 24 h prior to the procedure), immediately after the procedure, and then every 24 h until hospital discharge. Furthermore, patients were on continuous ECG monitoring during the entire hospitalization period following the procedure. All ECG tracings were analyzed by a cardiologist blinded to the clinical data. The diagnosis of intraventricular conduction abnormalities was based on recommendations from the Amer- ican Heart Association/American College of Cardiology Foundation/Heart Rhythm Society (AHA/ACCF/HRS) for the standardization and interpretation of ECGs (13) . The policies for permanent pacemaker implantation (PPI) were in accordance with the ACC/AHA/HRS guidelines for device-based therapy of cardiac rhythm abnormalities (14) .
Transient LBBB was defined as the occurrence of new LBBB that resolved before hospital discharge. Persistent LBBB was defined as any new-onset LBBB that persisted at hospital discharge. Those patients who developed LBBB after the procedure and required a PPI or died before hospital discharge (without proven resolution of the LBBB) were also included in the group of patients with persistent LBBB. were determined using a binary logistic regression model that included variables with a p value Յ0.10 on univariate analysis. Age, baseline QRS duration, and ventricular depth of the prosthesis were the variables included in the analysis. The predictors of significant LVEF changes over time were determined using a multivariate regression linear model that included variables with a p value Ͻ0.10 on univariate analysis. Hypertension, new-onset persistent LBBB and peak troponin T were the variables included in the analysis. Cumulative outcomes at 1-year follow-up were assessed by Kaplan-Meier estimates and compared using the log-rank test. A 30-day landmark analysis was also performed. The results were considered significant with p values Ͻ0.05. All analyses were conducted using the statistical package SAS version 9.2 (SAS Institute Inc., Cary, North Carolina).
Results
The baseline and procedural characteristics of the study population are shown in Table 1 . New-onset conduction disturbances and LBBB following TAVI. New-onset LBBB and overall conduction disturbances following TAVI are shown in Figure 1 . New-onset, complete LBBB was observed in 57 patients (28.2%) on the first ECG following the procedure, and an additional 4 patients developed new-onset LBBB at a mean of 24 Ϯ 17 h (range: 12 to 48 h) following TAVI, leading to a global incidence of new-onset LBBB during the hospitalization period of 30.2%. The ECG performed at hospital discharge showed the persistence and resolution of LBBB in 25 and 23 patients, respectively. At 6-to 12-month follow-up, no conduction disorders were observed in 65% of survivors at that time point. In patients with persistent LBBB at hospital discharge (nϭ25), LBBB had resolved in 12 patients (48%), 4 patients required PPI because of third-degree AVB (16%), and LBBB persisted in 9 patients (36%). No new-onset LBBB was documented in any patient after hospital discharge. The mean changes in QRS duration throughout the study period are shown in Figure 2 . Predictive factors of new-onset, persistent LBBB. Baseline and procedural characteristics of the patients, grouped according to the occurrence of persistent LBBB (vs. transient or no LBBB) following the TAVI procedure are shown in Table 2 Table 3 . At a median (range) follow-up of 12 (6 to 24) months, a total of 32 patients had died, with no differences between patients with and without persistent LBBB. There was 1 case of sudden death during the follow-up period, which occurred 9 months after TAVI in a patient with no LBBB at hospital discharge. Survival curves at 1-year follow-up are shown in Figures 3A and 3B . The overall rate of PPI was higher in patients with persistent LBBB compared to the rest of the study population (34.2 vs. 4.3%; p ϭ 0.001).
Freedom from PPI curves up to 1-year follow-up are shown in Figure 3C . Thirty-day landmark analyses for cumulative outcomes are shown in Figures 3D to 3F . Baseline and procedural characteristics of the patients grouped according to the need for PPI are shown in Table 4 . The occurrence of new-onset LBBB following the procedure (hazard ratio: 5.99; 95% CI: 2.93 to 15.61; p Ͻ 0.001) was the only factor associated with PPI during the entire study period.
Late Clinical outcomes of the 25 patients with persistent LBBB and no PPI at hospital discharge are detailed in Table 5 . None of these patients had sudden death at a median of 12 (6 to 24) months. However, the rates of syncope and the need for PPI during the follow-up period were higher in this group than in the rest of the study population (syncope: 16.0% vs. 0.7% [p ϭ 0.001]; PPI: 20.0% vs. 0.7%, p Ͻ 0.001). The individual characteristics of the patients requiring PPI during the follow-up period are shown in Table 6 . At 1-year follow-up, patients with persistent LBBB had a poorer New York Heart Association functional class compared to patients with no or transient LBBB (p ϭ 0.034) (Fig. 4) . Echocardiographic data. Valve hemodynamics of the patients with and without new-onset LBBB are shown in Figure 5 . The changes in LVEF throughout the study period are shown in Figure 6 . Patients with persistent Table 7 . In the multivariate linear regression analysis, the occurrence of persistent LBBB was the only independent predictive factor of decreased LVEF at 1-year follow-up (point estimate Ϯ standard error: -8.6 Ϯ 2.6; R 2 : 0.14; p ϭ 0.001).
Discussion
New-onset LBBB has been reported in 29% to 65% of the patients following TAVI with a self-expandable valve (1) (2) (3) (4) (5) (6) (7) (8) , and in 12% to 18% following TAVI with a balloonexpandable valve (3, 7, 9, 10) . The rate of 30% of new-onset LBBB observed in the present study might have been related mainly to the exclusion of patients with conduction abnormalities (including LBBB) or pacemaker prior to TAVI. In fact, the rate of new-onset LBBB in previous studies would have increased up to ϳ75% and 30% for In-Hospital Outcomes, According to the Occurrence of New-Onset LBBB Table 3 In-Hospital Outcomes, According to the Occurrence of New-Onset LBBB self-expandable and balloon-expandable valves, respectively, if patients with complete bundle branch block and/or pacemaker had been excluded (1-6,8 -10). Importantly, and in accordance with prior studies using balloon-expandable valves, a significant number of these conduction abnormalities resolved within the first few days following the intervention (9, 10) . In a further step, this study also shows that up to about one-half of the cases of new-onset LBBB present at hospital discharge (median: 7 days after TAVI) had resolved at 1-year follow-up. This finding clearly differs Values are mean Ϯ SD or n (%). *Distance between the hinge point of the mitral valve and the ventricular end of the valve prosthesis frame (TEE, long-axis view). AR ϭ aortic regurgitation; CI ϭ confidence interval; HR ϭ hazard ratio; other abbreviations as in Table 1 .
Late Clinic Outcomes, According to the Presence of New-Onset, Persistent LBBB (With No Pacemaker Implantation) at Hospital Discharge Values are median (interquartile range) or n (%). *Median (IQR).
Abbreviations as in Table 1 .
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important finding of the present study is the fact that no new intraventricular conduction disturbances were observed either after day 2 in the periprocedural period or later during the follow-up period.
Predictive factors of new-onset, persistent LBBB. Unlike all prior studies evaluating the predictive factors of LBBB (transient and persistent) following TAVI, this study specifically focused in the prediction of persistent LBBB compared with transient or absent LBBB. Of note, no predictive factors were encountered for transient LBBB, whereas both a lower (ventricular) valve positioning and longer QRS duration were associated with persistent LBBB following balloon-expandable valve implantation. A longer QRS duration might be associated with an early stage of the conduction system disease which, in turn, can increase the vulnerability of this system to any trauma during the TAVI procedure (16, 17) . A more ventricular positioning of the valve prosthesis might increase the risk for mechanical stress and direct damage of the conduction system, leading to a higher risk for conduction disturbances. In accordance with the results of this study, a lower positioning of the valve prosthesis has been shown to be a predictor of conduction disturbances and PPI in patients following TAVI with the self-expandable device (1, 6, 7) .
Prognostic value of new-onset, persistent LBBB. This study showed that the occurrence of new-onset, persistent LBBB following TAVI is associated with a much higher risk for complete AVB requiring PPI. It is of high clinical relevance that the higher risk for complete AVB started very soon (hours to days) after the appearance of LBBB, and 
Individual Characteristics of the Patients
Requiring PPI During the Follow-Up Period Abbreviations as in Tables 1 and 3 .
continued during the follow-up period in those patients with persistent LBBB. In fact, all but 1 case of complete AVB leading to PPI during the follow-up period occurred in patients with persistent LBBB, and syncope was the clinical presentation in most patients. While we found no relationship between the occurrence of LBBB and acute or late mortality following TAVI, and no cases of sudden death were reported among the patients with persistent LBBB. The potential usefulness of a closer follow-up (serial ECGs, 24-to 48-h ECG monitoring within the first months following TAVI), and/or systematic electrophysiologic studies in such cases should probably be investigated in the future. Patients with persistent LBBB had a significant impairment in LVEF during the follow-up period and exhibited a poorer functional status compared to those with no/ transient LBBB. Tzikas et al. (18) reported a lack of post-procedural improvement in LVEF in patients with new-onset conduction disturbances (LBBB and/or pacemaker implantation) after self-expandable valve implantation. It is known that the presence of LBBB generates a ventricular contraction asynchrony secondary to an abnormal electrical activation, which in turn causes left ventricular remodeling and further ventricular dysfunction (19) . The potential beneficial effects of resynchronization therapy (20) might merit evaluation in future studies. Study limitations. The results regarding the lack of a relationship between persistent LBBB and cardiac mortality, and particularly sudden death, should be interpreted with caution due to the relatively small sample size. These Values are mean Ϯ SD. CK-MB ϭ creatinine kinase-myocardial band; IVS ϭ interventricular septum; other definitions as in Table 1 .
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TAVI and Persistent LBBB results will therefore have to be confirmed in larger studies in the future.
Conclusions
In patients with aortic stenosis and no prior conduction abnormalities, new-onset LBBB occurred in up to 30% of patients following TAVI with a balloon-expandable valve, although this conduction disturbance was persistent in less than half of patients at 6-to 12-month follow-up. The ventricular depth of the prosthesis and QRS duration predicted the occurrence of persistent LBBB, which was associated with a higher rate of AVB and PPI, and poorer functional status and ventricular function at midterm follow-up. These results highlight the importance of close monitoring and follow-up of patients with persistent LBBB following TAVI and support the performance of larger studies to further evaluate the prognostic value of these conduction abnormalities following TAVI. 
